Not independent
Tenure on this board
1.8 yrs
Also a director at
Zai Lab Ltd (ZLAB)
Meeting calendar
ZBIO · Annual meeting · Monday, May 11, 2026
Zenas Biopharma Inc
9 nominees · 2 ballot items.
Elect two Class II directors (James Boylan and Patrick Enright) to serve until the 2029 Annual Meeting, and ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
Market cap
$1.9B
1Y TSR
+94.6%
Board grade
C
Record date
Mar 12, 2026
Filing
DEF 14A
Meeting concluded · May 11, 2026
Follow how the vote landed and what changed on Zenas Biopharma Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORTo elect the two Class II director nominees named in the Proxy Statement (James Boylan and Patrick Enright) to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORTo ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
1.8 yrs
Also a director at
Arrowhead Pharmaceuticals Inc (ARWR)
Independent
Tenure on this board
1.8 yrs
Also a director at
Compass Therapeutics Inc (CMPX)Immunome Inc (IMNM)
Independent
Tenure on this board
1.8 yrs
Also a director at
Jazz Pharmaceuticals PLC (JAZZ)Vera Therapeutics Inc (VERA)Bioage Labs Inc (BIOA)Veradermics Inc (MANE)
Independent
Tenure on this board
New nominee
Also a director at
Viridian Therapeutics Inc (VRDN)Apogee Therapeutics Inc (APGE)Spyre Therapeutics Inc (SYRE)Jade Biosciences Inc (JBIO)
Independent
Tenure on this board
1.8 yrs
Jake Nunn
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
1.8 yrs
Independent
Tenure on this board
0.7 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | FMR LLC | 11.6% | 7,293,152 | $143M |
| 2 | SR ONE CAPITAL MANAGEMENT, LP | 8.0% | 5,037,854 | $98M |
| 3 | NEA Management Company, LLC | 6.4% | 4,023,219 | $79M |
| 4 | Enavate Sciences GP, LLC | 6.2% | 3,919,159 | $77M |
| 5 | FEDERATED HERMES, INC. | 4.9% | 3,116,805 | $61M |
| 6 | Polar Capital Holdings Plc | 4.0% | 2,548,444 | $50M |
| 7 | Capital International Investors | 3.9% | 2,434,000 | $48M |
| 8 | Fairmount Funds Management LLC | 3.7% | 2,359,025 | $46M |
| 9 | NVP Associates, LLC | 2.9% | 1,838,482 | $36M |
| 10 | STATE STREET CORP | 2.3% | 1,470,923 | $29M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Zenas Biopharma Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Reference
Frequently asked questions
- When is the Zenas Biopharma Inc 2026 annual meeting?
- Zenas Biopharma Inc (ZBIO) holds its 2026 annual shareholder meeting on Monday, May 11, 2026.
- What is the record date for the Zenas Biopharma Inc 2026 meeting?
- The record date for the Zenas Biopharma Inc 2026 meeting is Thursday, March 12, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Zenas Biopharma Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Zenas Biopharma Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Zenas Biopharma Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Zenas Biopharma Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.